Real World Psilocybin Outcomes

States

This dashboard shows aggregate, real-world outcomes from licensed psilocybin services at healing centers in Oregon and Colorado, updated in real time as facilitators and centers record sessions. All figures are aggregated across participants; no individual-level data is shown. See Methods & data notes for how this data is collected and what it can and cannot show.

Showing real-world data from January 2025 through August 2026.

How these data are collected

Facilitators and centers in Oregon and Colorado record every session through the Althea platform, using a shared set of fields regardless of which state's program they operate under. That includes the safety and dosing information required by state law, such as dose administered and any adverse events during or after a session. Demographic information is collected in a standardized safety screening instrument.

Facilitators can also invite participants, on a voluntary basis, to complete short mental health questionnaires before their session and again two weeks after: the PHQ-9 for depression, the GAD-7 for anxiety, and the WHO-5 for general wellbeing. A separate questionnaire, the MEQ-30, captures the character of the experience itself and is sent about two days after the administration session.

Pre/post comparisons on this dashboard use strict pairing: only participants with both a baseline and a two-week post-journey score for the same instrument are included. GAD-7 and PHQ-9 are administered adaptively — they only appear when initial screening scores (GAD-2 ≥ 3 or PHQ-2 ≥ 3) indicate elevated symptoms, so fewer participants have paired scores for these instruments than for WHO-5.

This is live operational data

Facilitators and centers use the Althea platform as their day-to-day practice management system, for scheduling, intake, dosing records, and safety documentation. Because of that, the figures on this dashboard reflect real-time program activity rather than a periodic export or a one-time research pull, and update continuously as new sessions are recorded.

This dashboard does not represent the entire regulated psilocybin market in Oregon and Colorado. It reflects only the facilitators and centers who use the Althea platform to run their practice.

Researchers interested in more detailed analysis or participant-level data can contact the Althea team directly at info@withalthea.com.

How to read these numbers

Percent change describes the average change in a participant's own score, from their answers before a session to their answers two weeks later. It is a within-person comparison, not a comparison against a separate untreated group.

The “n” shown under each figure is the number of participants with a valid before-and-after pair for that specific measure. A larger n means the figure rests on a broader base of responses.

What this dashboard does not show

No control or placebo group. These are outcomes from people who chose to receive psilocybin services. There is no untreated comparison group in this dataset, so the figures cannot show how these participants would have fared without a session.
A two-week window. Follow-up scores are collected two weeks after a session. This dashboard does not speak to whether changes are sustained, fade, or shift beyond that point.
Self-selected follow-up. Completing the post-session questionnaire is optional. Participants who found their experience meaningful enough to check back in may be overrepresented relative to those who did not.
Self-reported scores. All measures are self-report instruments, which carry the same inherent bias as any self-report data, in research or in clinical care.
A self-selected population. Participants sought out and paid for regulated psilocybin services; they are not a random sample of the public. The group is predominantly white, and more than half traveled from outside Oregon or Colorado to receive care, which reflects who currently has access rather than who might benefit.